MCI-186 (Edaravone)

SKU: orb1310644

Description

Edaravone (MCI-186) is a potent free radical scavenger clinically used for acute ischemic stroke. It is widely applied in neuroscience research to study oxidative stress mechanisms in models of cerebral infarction, both in vitro and in vivo.

Research Area

Cell Biology, Neuroscience

Key Properties

• CAS Number: 89-25-8
• MW: 174.20
• Purity: >98%
• Formula: C₁₀H₁₀N₂O
• SMILES: CC1=NN(C(=O)C1)C1=CC=CC=C1
• Target: Antioxidant
• Solubility: Soluble in DMSO (up to 20 mg/ml).

Bioactivity

• In Vivo:
  Edaravone optimizes the state of NOS by reducing the detrimental isoforms iNOS and nNOS, while increasing the beneficial eNOS, thus favoring neuroprotection in ischemic stroke. It inhibits oxidation and enhances eNOS expression without boosting production, improving and preserving cerebral blood flow during reperfusion without necessitating peroxynitrite formation. Edaravone exerts its neuroprotective effect by mitigating neuronal damage from cerebral ischemia and inhibiting endothelial injury.
• In Vitro:
  Edaravone significantly improves neurological function in animals. Treatment with edaravone substantially reduces TUNEL-positive apoptotic cells and increases the expression of Bcl-2, while decreasing the immunoreactivity of Bax protein in the peri-infarct area. The research demonstrates that edaravone provides excellent protection against ischemic/reperfusion-induced brain injury through a Bcl-2/Bax protein-dependent anti-apoptotic mechanism. Following a 24-hour infusion of edaravone into murine brain tissue, there is a notable reduction in infarct volume and amelioration of neurological deficits. In the early stages post-reperfusion, edaravone significantly inhibits the accumulation of HNE-modified proteins and 8-OHdG in the penumbral region, reduces the expression of iNOS, diminishes microglial activation, and lowers the formation of nitrotyrosine. Edaravone also markedly attenuates renal function and pathological outcomes in rat kidneys, significantly reducing free radical production in renal tubular epithelial cells as indicated by fluorescence.
• Cell Research:
  Cell viability is quantified by MTT assay and trypan blue staining. MTT (5 mg/mL, 20 μL) is added to each well and incubated for 4 h at 37°C after the drug treatments. The medium is removed and the cell pellet is dissolved in DMSO. Then, the optical density (OD) values are measured at 570 nm using an ELISA reader.

Storage & Handling

• Storage: RT
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Edaravone

Compound Identifiers

PubChem CID

4021